BACKGROUND AND OBJECTIVES: Brachial plexus tumors represent a challenge for neurosurgeons because of complex anatomy, risks during surgery, and limited evidence-based guidance in managing these rare tumors. We aim to investigate the clinical characteristics, complications, and neurological outcomes of surgical resection of benign brachial plexus tumors. METHODS: We reviewed the medical records of patients diagnosed with benign brachial plexus tumors at (Johns Hopkins Medical Institutes) from July 2014 to April 2023. Of 123 screened patients, those who had surgical resection for benign brachial plexus tumors were identified. RESULTS: A total of 56 patients were included. Their mean (SD) age was 46.79 years (14.67), and 60.7% were women. The most common initial presentations were palpable mass (82.1%) and pain (66.1%). Sensory and motor deficits were reported in 27 (48.2%) and 12 patients (21.4%), respectively. Gross total resection was achieved in 53 patients (94.6%), and en bloc approach was performed in 39 patients (69.6%). Three patients developed postoperative complications, including hematoma, wound infection, and persistent sinus tachycardia, with no recorded deaths nor significant neurological deficits. With a mean follow-up of 38.08 (39.93) months after the surgery, 35 patients (94.6%) reported improvements in their preoperative pain, and 20 patients (54.1%) had total pain relief. Among those with preoperative neurological deficits, the recovery from sensory deficits was documented in 18 patients (66.7%), with better outcomes observed with preoperative dysesthesias rather than paresthesias, and the motor strength recovery rate was 83.3%. Two patients developed new sensory deficits, whereas no new motor deficits were reported. Tumor recurrence was reported in 1 patient (1.8%). CONCLUSION: Brachial plexus tumors can be cured surgically by gross total resection with favorable outcomes, minimal complications, and low incidence of recurrence.